Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs.

Henjes, F; Bender, C; von der Heyde, S; Braun, L; Mannsperger, H A; Schmidt, C; Wiemann, S; Hasmann, M; Aulmann, S; Beissbarth, T; Korf, U

Henjes, F; Bender, C; von der Heyde, S; Braun, L; Mannsperger, H A; Schmidt, C; Wiemann, S; Hasmann, M; Aulmann, S; Beissbarth, T; Korf, U.

Henjes F; Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Oncogenesis ; 1: e16, 2012 Jul 02.

Article en En | MEDLINE | ID: mdl-23552733

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412653
https://dx.doi.org/10.1038/oncsis.2012.16

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Año: 2012 Tipo del documento: Article

Texto completo

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412653
https://dx.doi.org/10.1038/oncsis.2012.16

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Año: 2012 Tipo del documento: Article